Commentary: A historical review of centers for disease control and prevention antiviral treatment and postexposure chemoprophylaxis guidance for human infections with novel influenza a viruses associated with severe human disease

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S575-S580

  Havers, Fiona P ^a   Campbell, Angela P ^a   Uyeki, Timothy M ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiviral treatment; Avian influenza; Neuraminidase inhibitors

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ARTICLE; AVIAN INFLUENZA (H5N1); AVIAN INFLUENZA VIRUS; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA A (H7N9); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H5N2); INFLUENZA A VIRUS (H5N8); NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UNITED STATES; ANIMAL; BIRD; DRUG EFFECTS; EPIDEMIOLOGY; INFLUENZA A VIRUS (H7N9); INFLUENZA IN BIRDS; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHEMOPREVENTION; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 85030611497     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix065     Document Type: Article

References (76)

1. Munoz O, De Nardi M, van der Meulen K, et al.; FLURISK Consortium. Genetic adaptation of influenza A viruses in domestic animals and their potential role in interspecies transmission: A literature review. Ecohealth 2016; 13:171-98.
2. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76:105-15.
3. Centers for Disease Control and Protection. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. http://www.cdc.gov/flu/avianflu/novel-Av-Treatment-guidance.htm. Accessed 12 January 2017.
4. Centers for Disease Control and Protection. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. https://www.cdc.gov/flu/avianflu/novel-Av-chemoprophylaxis-guidance.htm. Accessed 12 January 2017
5. Centers for Disease Control and Protection.Interim guidance on influenza antiviral chemoprophylaxis of persons exposed to birds with avian influenza A viruses associated with severe human disease or with the potential to cause severe human disease. Available at: http://www.cdc.gov/flu/avianflu/guidance-exposed-persons.htm. Accessed 21 October 2016
6. World Health Organization. Influenza at the human-Animal interface: summary and assessment, 22 November to 19 December 2016. http://www.who.int/influenza/human animal interface/Influenza Summary IRA HA interface 12 19 2016.pdf?ua=1. Accessed 23 January 2017.
7. Yang ZF, Mok CK, Peiris JS, Zhong NS. Human infection with a novel Avian influenza A(H5N6) virus. N Engl J Med 2015; 373:487-9.
8. Chen H, Yuan H, Gao R, et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: A descriptive study. Lancet 2014; 383:714-21.
9. Jhung MA, Epperson S, Biggerstaff M, et al. Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis 2013; 57:1703-12.
10. Centers for Disease Control and Protection. Variant influenza viruses in humans. https://www.cdc.gov/flu/swineflu/variant-flu-in-humans.htm. Accessed 12 January 2017.
11. Lai S, Qin Y, Cowling BJ, et al. Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: A systematic review of individual case data. Lancet Infect Dis 2016; 16:e108-18.
12. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza AV. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
13. Approaches to controlling, preventing and eliminating H5N1 highly pathogenic avian influenza in endemic countries. Rome, Italy: FAO, 2011. http://www.fao.org/docrep/014/i2150e/i2150e00.htm. Accessed 21 October 2016.
14. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2016. http://www.who.int/influenza/human animal interface/2016 12 19 tableH5N1.pdf?ua=1. Accessed 23 January 2017.
15. Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 2006; 12:1841-7.
16. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable erson-To-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
17. Olsen SJ, Ungchusak K, Sovann L, et al. Family clustering of avian influenza A (H5N1). Emerg Infect Dis 2005; 11:1799-801.
18. Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis 2011; 53:1237-44.
19. Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis 2009; 199:1726-34.
20. Beigel JH, Farrar J, Han AM, et al.; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
21. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Geneva, Switerland: World Health rganization, 2007
22. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. http://www.who.int/medicines/publications/WHO PSM PAR 2006.6.pdf. Accessed 12 January 2017.
23. Avian influenza tool kit: responding to human cases of A/H5N1. Stockholm, Sweden: European Centre for Disease Prevention and Control (ECDC), 2007. http://ecdc.europa.eu/en/healthtopics/avian influenza/public health measures/Pages/Public health measures.aspx. Accessed 12 January 2017
24. Investigation & management of possible human cases of avian infuenza A/H5N1. London, England: Public Health England, 2012. https://www.gov.uk/government/publications/avian-influenza-guidance-And-Algorithms-for-managing-human-cases. Accessed 12 January 2017
25. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-24.
26. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
27. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-50.
28. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: A randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109-18.
29. Fry AM, Goswami D, Nahar K, et al. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial. Lancet Infect Dis 2015; 15:654-62.
30. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: Analysis of a global patient registry. J Infect Dis 2010; 202:1154-60.
31. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359-66.
32. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7.
33. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007;13:1354-7
34. White NJ, Webster RG, Govorkova EA, Uyeki TM. What is the optimal therapy for patients with H5N1 influenza? PLoS Med 2009; 6:e1000091
35. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
36. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin Infect Dis 2013; 57:1511-9.
37. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
38. Welch SC, Lam SW, Neuner EA, Bauer SR, Bass SN. High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. Intensive Care Med 2015; 41:1365-6.
39. Noel ZR, Bastin ML, Montgomery AA, Flannery AH. Comparison of high-dose versus standard dose oseltamivir in critically ill patients with influenza. J Intensive Care Med 2016.
40. GlaxoSmithKline. Full prescribing information: Relenza. Research Triangle Park. NC: GlaxoSmithKline 2010
41. Gu J, Xie Z, Gao Z et al. H5N1 infection of the respiratory tract and beyond: A molecular pathology study. Lancet 2007; 370:1137-45.
42. de Jong MD, Bach VC, Phan TQ et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352:686-91.
43. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill mmunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50: 1493-6.
44. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362:88-9.
45. Harper SA, Bradley JS, Englund JA, et al.; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
46. Welliver R, Monto AS, Carewicz O, et al.; Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial. JAMA 2001;285:748-54
47. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-9
48. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-8
49. Hayden FG, Gubareva LV, Monto AS, et al.; Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343:1282-9.
50. Gao R, Cao B, Hu Y, et al. Human Infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
51. Li Q, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014; 370:520-32.
52. Liu B, Havers F, Chen E, et al. Risk factors for influenza A(H7N9) disease-China, 2013. Clin Infect Dis 2014; 59:787-94.
53. Zhou L, Ren R, Ou J, et al. Risk factors for influenza A(H7N9) disease in China, a matched case control study, October 2014 to April 2015. Open Forum Infect Dis 2016; 3:ofw182.
54. Liu B, Havers F, Zhou L, et al. Clusters of human infections with avian influenza A(H7N9) virus in China, March 2013-June 2015. J Infect Dis 2017.
55. Qin Y, Horby PW, Tsang TK, et al. Differences in the epidemiology of human cases of avian influenza A(H7N9) and A(H5N1) viruses infection. Clin Infect Dis 2015; 61:563-71.
56. Qi X, Qian YH, Bao CJ, et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ 2013; 347:f4752.
57. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85
58. Cowling BJ, Jin L, Lau EH, et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: A population-based study of laboratory-confirmed cases. Lancet 2013; 382:129-37.
59. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina 2009. MMWR Morb Mortal Wkly Rep 2009 58 969-72
60. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296-7.
61. Centers for Disease Control and Protection. Influenza antiviral medications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
62. Centers for Disease Control and Protection. Avian influenza: information for health professionals and laboratorians. http://www.cdc.gov/flu/avianflu/healthprofessionals.htm
63. Cané A, Casanueva E, Iolster T, et al. First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina. Pediatr Infect Dis J 2010; 29:384
64. Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-Treated patient in Taiwan. J Infect Dis 2015; 211:249-57.
65. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-9.
66. Zhang X, Song Z, He J, et al. Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerg Microbes Infect 2014; 3:e78
67. Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 2008; 197:1315-23.
68. World Health Organization. Avian influenza A(H7N9) virus: post-exposure antiviral chemoprophylaxis of close contacts of a patient with confirmed H7N9 virus infection and/or high risk poultry/environmental exposures. http://www.who.int/influenza/human animal interface/influenza h7n9/publication/en/Accessed 12 January 2017.
69. Public Health England. Guidance note: prophylaxis for close contacts of confirmed cases of avian influenza A(H7N9). https://www.gov.uk/government/uploads/system/uploads/attachment data/file/358674/Guidance note rationale for change to Ah7n9 prophylaxis 0.pdf
70. US Food and Drug Administration. Tamiflu (oseltamivir phosphate) [package insert]. http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm147992.pdf. Accessed 26 October 2016
71. Jhung MA, Nelson DI; Centers for Disease Control and Prevention (CDC). Outbreaks of avian influenza A (H5N2), (H5N8), and (H5N1) among birds-United States, December 2014-January 2015. MMWR Morb Mortal Wkly Rep 2015;64:111
72. Lee DH, Bahl J, Torchetti MK, et al. Highly pathogenic avian influenza viruses and generation of novel reassortants, United States, 2014-2015. Emerg Infect Dis 2016; 22:1283-5.
73. Bevins SN, Dusek RJ, White CL, et al. Widespread detection of highly pathogenic H5 influenza viruses in wild birds from the Pacific Flyway of the United States. Sci Rep 2016; 6:28980.
74. Torchetti MK, Killian ML, Dusek RJ, et al. Novel H5 clade 2.3.4.4 reassortant (H5N1) virus from a green-winged teal in Washington, USA. Genome Announc 2015; 3:e00195-15.
75. US Department of Agriculture. HPAI 2014/15 confirmed detections. https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal disease information/avian influenza disease/sa detections by states/hpai 2014 2015 confirmed detections.Accessed 4 August 2016
76. Arriola CS, Nelson DI, Deliberto TJ, et al.; H5 Investigation Group. Infection risk for persons exposed to highly pathogenic avian influenza A H5 virus-infected birds, United States, December 2014-March 2015. Emerg Infect Dis 2015; 21:2135-40.